Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 77 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atrial Fibrillation and Flutter Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Impact of an Atrial Fibrillation Decision Support Tool (AFDST) on Thromboprophylaxis for Atrial Fibrillation

NCT02524977
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Decision Support, Educational Intervention Only
Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 24, 2026, 6:32 PM EDT
Completed No phase listed Observational

Propagation ANalysis for Arrhythmogenic Conduction Elimination to Prevent Atrial Flutter and Fibrillation (PANACEA-AF)

NCT03737838
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Atrial fibrillation ablation
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 24, 2026, 6:32 PM EDT
Enrolling by invitation Not applicable Interventional

Storytelling for Reducing Gap in Anticoagulation Use in African Americans With Atrial Fibrillation

NCT05997914
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter, Adherence, Medication, Anticoagulants and Bleeding Disorders, Stroke, Bleeding, Narration
Interventions
Storytelling Intervention
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Jacksonville, Florida • Worcester, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 24, 2026, 6:32 PM EDT
Completed No phase listed Observational

Novel Cardiac Signal Processing System

NCT04112433
View directory record Official record
Conditions
Cardiac Arrhythmia
Interventions
PURE EP 2
Device
Lead sponsor
BioSig Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Jacksonville, Florida • Boston, Massachusetts • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 24, 2026, 6:32 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

HeartBeam ECG Registry

NCT07501299
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter, Bradycardia, Tachycardia, Arrhythmia
Interventions
Electrocardiogram (ECG)
Diagnostic Test
Lead sponsor
HeartBeam, Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 24, 2026, 6:32 PM EDT
Completed Phase 3 Interventional

Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Male Subjects

NCT00126061
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Tedisamil sesquifumarate
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
4
States / cities
Los Angeles, California • Santa Ana, California • Honolulu, Hawaii + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 24, 2026, 6:32 PM EDT
Completed Phase 3 Interventional

Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter

NCT00115791
View directory record Official record
Conditions
Atrial Flutter, Atrial Fibrillation
Interventions
RSD1235, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
19
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2008 · Synced Oct 24, 2026, 6:32 PM EDT
Terminated No phase listed Observational

Data Collection Atrial Fibrillation Exploratory Study

NCT03647085
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Wearable cardiac monitor
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 24, 2026, 6:32 PM EDT
Completed No phase listed Observational

Stanford Cardiac Invasive Electrophysiology Novel Computer Experience

NCT03549806
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Tachycardia, Atrial Flutter, Arrhythmias, Cardiac
Interventions
No Intervention. Test is computer algorithm.
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 24, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available

Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

NCT01970501
View directory record Official record
Conditions
Current or Recent History of Atrial Fibrillation
Interventions
bucindolol hydrochloride, metoprolol succinate, Placebo oral capsule
Drug · Other
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
48
States / cities
Anchorage, Alaska • Phoenix, Arizona • East Palo Alto, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 24, 2026, 6:32 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Get With the Guidelines Atrial Fibrillation Registry

NCT06245187
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
GWTG Atrial Fibrillation program
Other
Lead sponsor
American Heart Association
Other
Eligibility
18 Years to 125 Years
Enrollment
17,198 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2040
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 24, 2026, 6:32 PM EDT
Active, not recruiting Not applicable Interventional

Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

NCT06735534
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
FARAPULSE™ Pulsed Field Ablation System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
33
States / cities
Mobile, Alabama • Jonesboro, Arkansas • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 6:32 PM EDT
Completed Phase 3 Interventional

Ablation of Perimitral Flutter Following Catheter Ablation of Atrial Fibrillation: Impact on Outcomes

NCT01173796
View directory record Official record
Conditions
Atrial Fibrillation, Perimitral Flutter
Interventions
catheter ablation
Procedure
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Oct 24, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available

A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation

NCT04213807
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
MAA868 Cohort 1, MAA868 Cohort 2, MAA868 Cohort 3, Placebo
Biological · Other
Lead sponsor
Anthos Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Beverly Hills, California • Wichita, Kansas • Alexandria, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 24, 2026, 6:32 PM EDT
Not listed Phase 2Phase 3 Interventional

Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation

NCT00691470
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter, Venous Thromboembolic Disease, Myocardial Infarction, Cardiomyopathy
Interventions
ATI-5923, Coumadin (warfarin)
Drug
Lead sponsor
ARYx Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Oct 24, 2026, 6:32 PM EDT
Recruiting Not applicable Interventional

Intra-abdominal Pressure (IAP) During PFA Treatment of A-fib/ A-Flutter

NCT06876896
View directory record Official record
Conditions
Intra-Abdominal Hypertension
Interventions
Accuryn Foley catheter device
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 24, 2026, 6:32 PM EDT
Completed Not applicable Interventional

Confirm Rx™ Versus Reveal LINQ™ - Which is More Reliable in Data Transmission? A Randomized Clinical Study

NCT03720639
View directory record Official record
Conditions
Cardiac Arrythmias, Syncope, Atrial Fibrillation, Atrial Flutter, Tachycardia, Stroke
Interventions
Abbott, Inc Confirm Rx™ versus Medtronic, Inc Reveal LINQTM
Device
Lead sponsor
Sparrow Clinical Research Institute
Other
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Lansing, Michigan • Traverse City, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 24, 2026, 6:32 PM EDT
Active, not recruiting Not applicable Interventional

RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.

NCT05883631
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Fibrillation, Persistent, Atrial Fibrillation Paroxysmal, Arrhythmia, Arrhythmias, Cardiac, Atrial Flutter, Atrial Fibrillation, Paroxysmal or Persistent, Atrial Arrhythmia, Atrial Tachycardia
Interventions
Electrographic Flow (EGF) mapping and ablation of EGF-identified sources of Atrial Fibrillation, Electrographic Flow (EGF) mapping (no ablation)
Device
Lead sponsor
Cortex
Industry
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Redwood City, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 24, 2026, 6:32 PM EDT
Completed Phase 3 Interventional Results available

A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation

NCT00174785
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
dronedarone (SR33589), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
70 Years and older
Enrollment
4,628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Oct 24, 2026, 6:32 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Pulmonary Vein Isolation To Reduce Future Risk Of Atrial Fibrillation In Patients Undergoing Typical Flutter

NCT01710150
View directory record Official record
Conditions
Typical Atrial Flutter, Risk Factors With Future Development of Atrial Flutter
Interventions
CTI ablation alone, CTI ablation and Pulmonary vein isolation (PVI)
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 24, 2026, 6:32 PM EDT
Completed Phase 2 Interventional

Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr

NCT00232310
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
CELIVARONE (SSR149744C)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 8, 2012 · Synced Oct 24, 2026, 6:32 PM EDT
Completed Phase 3 Interventional

Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects

NCT00126022
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Tedisamil sesquifumarate
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Tullahoma, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 24, 2026, 6:32 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm

NCT02454283
View directory record Official record
Conditions
Atrial Fibrillation or Flutter
Interventions
Vanoxerine HCl, Placebo
Drug
Lead sponsor
Laguna Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
4
States / cities
Littleton, Colorado • Washington D.C., District of Columbia • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 24, 2026, 6:32 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter

NCT01914926
View directory record Official record
Conditions
Heart Rate and Rhythm Disorders
Interventions
Metoprolol, Diltiazem
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Oct 24, 2026, 6:32 PM EDT